Literature DB >> 3038304

Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.

D M Sullivan, M D Latham, W E Ross.   

Abstract

We have shown previously that quiescent Chinese hamster ovary (CHO) cells are less sensitive than log phase CHO cells to the cytotoxic and DNA cleavage effects of etoposide, a drug which appears to act via DNA topoisomerase II. This loss of sensitivity was associated with a decrease in topoisomerase enzyme activity in nuclear extracts of the quiescent cells. We have now extended our observations by examining the basis for the reduction in enzyme activity during quiescence. DNA topoisomerase II content, as assayed by immunoblotting with a polyclonal rabbit anti-topoisomerase II antiserum, was virtually absent in nuclear extracts of quiescent CHO cells in contrast to logarithmically growing cells. This suggests that the previously demonstrated loss of enzyme activity in CHO cells is a function of reduction in content rather than posttranslational modifications of the enzyme. Quiescent human lymphoblastic CCRF cells also exhibited reduced topoisomerase II content compared to actively proliferating cultures, but the difference was less than that observed in CHO cells. In contrast, log and plateau phase cultures of mouse leukemia L1210 cells exhibited similar topoisomerase II content. Reduction in enzyme content correlated with the ability of these cell lines to accumulate during quiescence with a G0-G1 content of DNA. Sensitivity to the DNA cleavage effects of etoposide in dividing and nondividing cells correlated well with enzyme content. As has been observed with CHO cells, both CCRF and L1210 cells in plateau phase were more resistant to the cytotoxic effects of etoposide than those actively dividing. The result with L1210 cells was surprising, however, in light of the equivalent DNA damage observed under the two growth conditions. Our data indicate that topoisomerase II enzyme content is proliferation dependent in some but not all cells and suggest that while enzyme content may be important in drug resistance in some cell types, other factors can decrease the sensitivity of the cell to cleavable complex formation as well.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038304

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Antitrypanosomal activity of fluoroquinolones.

Authors:  E Nenortas; C Burri; T A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response.

Authors:  J W Shen; J R Subjeck; R B Lock; W E Ross
Journal:  Mol Cell Biol       Date:  1989-08       Impact factor: 4.272

3.  Topoisomerase II alpha and II beta expression in childhood acute lymphoblastic leukaemia: relation to prognostic factors and clinical outcome.

Authors:  A J Lodge; A G Hall; M M Reid; G G McIntosh; M Steward; J J Anderson; C H Horne; B Angus
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

4.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

Review 5.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

6.  Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent.

Authors:  S N Ebert; S S Shtrom; M T Muller
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.

Authors:  J Schaak; P Schedl; T Shenk
Journal:  Nucleic Acids Res       Date:  1990-03-25       Impact factor: 16.971

Review 8.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

9.  Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line.

Authors:  C D Evans; S E Mirski; M K Danks; S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.